Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Exemestane

Exemestane

Exemestane (Aromasin): a steroidal aromatase inhibitor approved in 1999 for breast cancer, with label warnings, evidence and WADA status.

FDA-approved, prescription only · Evidence grade A · Reviewed

Approved and studied uses
  • FDA-approvedBreast cancerPostmenopausal women

Exemestane (Aromasin). Aromatase inhibitor.

AFDA-approved, prescription only. Evidence grade A: approved, large human trials.

What is Exemestane?

Exemestane is an oral, steroidal aromatase inhibitor. It binds the aromatase enzyme and blocks estrogen production.

Is Exemestane FDA-approved?

FDA approved Aromasin (NDA 020753) on October 21, 1999; Pfizer now holds the application. It is approved for breast cancer in postmenopausal women, in the adjuvant setting after prior tamoxifen and for advanced disease. Generics are sold, and it is prescription only. Use in men or to manage steroid side effects is not an approved use.

What does the evidence show for Exemestane?

Randomized trials in postmenopausal women with breast cancer support the approved uses.

What are the known risks of Exemestane?

The label has no boxed warning. It warns of loss of bone mineral density over time and of harm to an unborn baby, and older labels said not to give it to premenopausal women. WADA prohibits aromatase inhibitors at all times in class S4, hormone and metabolic modulators.

How is Exemestane measured?

A tablet, so there is nothing to draw or calculate.

Sources: Drugs@FDA: Aromasin (NDA 020753); FDA: Aromasin prescribing information (2024); WADA: The Prohibited List. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.